Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
152.80    -0.20 (-0.13%)
Bid:
153.20
Ask:
153.60
Spread: 0.40 (0.261%)
Market Cap: £874.50m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

AGM Trading Statement

26 Apr 2022 07:00

RNS Number : 2756J
Elementis PLC
26 April 2022
 

Elementis plc

AGM Trading Statement

 

Robust first quarter trading performance

 

Chromium strategic review

 

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues a trading update for the three months ended 31 March 2022 and announces a strategic review of Chromium.

First Quarter Business Performance

 

Trading for the three months ended 31 March 2022 has been positive. Revenue increased approximately 7% on an underlying basis* against the prior year period, driven by pricing actions, new business wins and continued demand recovery in Personal Care.

· Coatings revenue and margins increased on the prior year period. Successful pricing actions and an improved mix more than offset lower volumes linked to supply chain disruptions and weaker industrial activity in China, as well as rising raw material, energy and logistics cost inflation.

 

· Personal Care performance improved materially as social restrictions eased further and our growth initiatives continued to gain momentum. Margins were strong due to successful pricing actions. The ramp-up of our new plant in India continues to progress at pace.

 

· In Talc, while successful pricing actions more than offset cost inflation, performance declined on the prior year period due to weaker European automotive production and a strike throughout the first quarter at our main paper customer in Finland.

 

· Chromium performance declined as an unexpected temporary plant outage impacted volumes. Pricing continued to show positive momentum, more than offsetting increased costs.

 

Cash generation in the first quarter was in line with expectations and the Group's business model remains highly cash generative.

 

Strategic Update

 

The Group today announces it has initiated a strategic review of its Chromium business. The review will establish whether the full potential of Chromium can best be delivered as part of Elementis, or, via a full or partial divestment. It will consider the practicality of all options, whilst prioritising the best interests of all stakeholders, including employees, customers and shareholders.

 

Outlook

 

The year has started well with improved profitability, driven by self-help actions, positive momentum in Personal Care and underlying strength in Coatings. For the full year, we are confident that further strategic progress will drive improved financial performance and a reduction in leverage, in line with expectations.

 

Commenting on today's announcement, CEO, Paul Waterman said,

 

"We have made a good start to the year and will continue to maintain our focus on self-help actions and effectively managing the challenging external supply chain environment, demand uncertainties and rising inflation. We remain on-track to deliver $50m of new business opportunities, over 20 new products and progress towards $10m of additional efficiency savings by 2023.

 

In line with our Innovation, Growth and Efficiency strategy, we have focused Elementis on high quality Personal Care, Coatings and Talc performance additive businesses which hold enduring positions of strength in growing markets, and today represent approximately 90% of Group profits. In this context we will execute a strategic review of our Chromium business to determine whether Elementis remains the best owner."

 

Enquiries

Elementis

James Curran, Investor Relations 020 7067 2994

Tulchan

Martin Robinson 020 7353 4200

Olivia Peters

 

Notes: Adjusted for constant currency impact

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFSDSEIEFIF
Date   Source Headline
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares
24th Nov 20256:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.